Company profile: EIP Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage therapeutics for neurodegenerative diseases, centered on neflamapimod, an oral p38 alpha inhibitor aimed at reversing synaptic dysfunction; conducting Phase 2b trials (RewinD-LB in dementia with Lewy bodies, REVERSE-SD in early-stage Alzheimer’s) and exploring stroke recovery by enhancing neural plasticity.
Products and services
- Neflamapimod: Engineers an oral therapy inhibiting the p38 alpha enzyme to reverse synaptic dysfunction for treating neurodegenerative diseases
- REVERSE-SD Phase 2b: Executes a Phase 2b clinical trial assessing neflamapimod’s impact on synaptic dysfunction and episodic memory in early-stage Alzheimer’s disease patients
- RewinD-LB Phase 2b Clinical Trial: Conducts a Phase 2b study of neflamapimod in dementia with Lewy bodies, focusing on dementia severity and motor function
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to EIP Pharma
Protembis
HQ: Germany
Website
- Description: Provider of a catheter-based cerebral protection system (ProtEmbo) that deflects embolic material away from the cerebrovascular circulation during left-sided heart procedures, particularly transcatheter aortic valve replacement (TAVR).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protembis company profile →
Vitro Biopharma
HQ: United States
Website
- Description: Provider of stem cell therapy, cell lines, and cell culture media, including AlloRx Stem Cell therapy from Wharton’s jelly–derived MSCs for autoimmune and inflammatory disorders; MSC-Gro specialty media for MSC growth and expansion; research-grade cancer-associated and native fibroblasts; human umbilical cord and placenta-derived MSC lines; and MSC-Gro formulations (low serum, serum-free, CAF-specific).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitro Biopharma company profile →
Aequus Pharmaceuticals
HQ: Canada
Website
- Description: Provider of ophthalmology and transplant treatments and devices, offering Tacrolimus IR for organ rejection prophylaxis and refractory rejection; Vistitan and Zimed PF (bimatoprost 0.03%) to reduce intraocular pressure; Evolve preservative-free lubricating eye drops; the Zepto Capsulotomy System for cataract surgery; and REV-0100, a potential therapy for Stargardt disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aequus Pharmaceuticals company profile →
Magnus Medical
HQ: United States
Website
- Description: Provider of closed-loop neuromodulation technology for intractable neurological and psychiatric disorders. Offers the SAINT Neuromodulation System, a non-invasive magnetic stimulation treatment targeting brain areas associated with depression and delivered over five days, and the Open Label Optimization (OLO) clinical research program evaluating SAINT's effectiveness in Major Depressive Disorder.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Magnus Medical company profile →
Amylyx Pharmaceuticals
HQ: United States
Website
- Description: Provider of solutions for Alzheimer’s and other brain diseases, offering ALS treatments such as RELYVRIO (U.S.)/ALBRIOZA (Canada) and AMX0035, a combination of sodium phenylbutyrate and taurursodiol studied for ALS and other neurodegenerative diseases, plus a patient support program with assistance and a free drug program for eligible patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amylyx Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for EIP Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to EIP Pharma
2.2 - Growth funds investing in similar companies to EIP Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for EIP Pharma
4.2 - Public trading comparable groups for EIP Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →